Tajeu Gabriel S, Kent Shia T, Kronish Ian M, Huang Lei, Krousel-Wood Marie, Bress Adam P, Shimbo Daichi, Muntner Paul
From the Department of Epidemiology, University of Alabama at Birmingham (G.S.T., S.T.K., L.H., P.M.); Department of Medicine, Center for Behavioral Cardiovascular Health, Columbia University Medical Center, New York, NY (I.M.K., D.S.); Department of Medicine, Tulane University School of Medicine, New Orleans, LA (M.K.-W.); Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA (M.K.-W.); Research Division, Ochsner Clinic Foundation, New Orleans, LA (M.K.-W.); and Departments of Population Health Sciences and Pharmacotherapy, University of Utah, Salt Lake City (A.P.B.).
Hypertension. 2016 Sep;68(3):565-75. doi: 10.1161/HYPERTENSIONAHA.116.07720. Epub 2016 Jul 18.
Low antihypertensive medication adherence is common. During recent years, the impact of low medication adherence on increased morbidity and healthcare costs has become more recognized, leading to interventions aimed at improving adherence. We analyzed a 5% sample of Medicare beneficiaries initiating antihypertensive medication between 2007 and 2012 to assess whether reductions occurred in discontinuation and low adherence. Discontinuation was defined as having no days of antihypertensive medication supply for the final 90 days of the 365 days after initiation. Low adherence was defined as having a proportion of days covered <80% during the 365 days after initiation among beneficiaries who did not discontinue treatment. Between 2007 and 2012, 41 135 Medicare beneficiaries in the 5% sample initiated antihypertensive medication. Discontinuation was stable during the study period (21.0% in 2007 and 21.3% in 2012; P-trend=0.451). Low adherence decreased from 37.4% in 2007 to 31.7% in 2012 (P-trend<0.001). After multivariable adjustment, the relative risk of low adherence for beneficiaries initiating treatment in 2012 versus in 2007 was 0.88 (95% confidence interval, 0.83-0.92). Low adherence was more common among racial/ethnic minorities, beneficiaries with Medicaid buy-in (an indicator of low income), and those with polypharmacy, and was less common among females, beneficiaries initiating antihypertensive medication with multiple classes or a 90-day prescription fill, with dementia, a history of stroke, and those who reached the Medicare Part D coverage gap in the previous year. In conclusion, low adherence to antihypertensive medication has decreased among Medicare beneficiaries; however, rates of discontinuation and low adherence remain high.
抗高血压药物依从性低的情况很常见。近年来,药物依从性低对发病率增加和医疗成本的影响已得到更多认识,从而引发了旨在提高依从性的干预措施。我们分析了2007年至2012年间开始服用抗高血压药物的医疗保险受益人的5%样本,以评估停药和低依从性是否有所减少。停药定义为在开始用药后的365天中的最后90天没有抗高血压药物供应。低依从性定义为在开始用药后的365天内,未停药的受益人中有<80%的天数有药物覆盖。在2007年至2012年间,5%样本中的41135名医疗保险受益人开始服用抗高血压药物。在研究期间,停药情况稳定(2007年为21.0%,2012年为21.3%;P趋势=0.451)。低依从性从2007年的37.4%降至2012年的31.7%(P趋势<0.001)。经过多变量调整后,2012年开始治疗的受益人相对于2007年开始治疗的受益人,低依从性的相对风险为0.88(95%置信区间,0.83 - 0.92)。低依从性在少数族裔、有医疗补助购买资格(低收入指标)的受益人以及服用多种药物的人群中更为常见,而在女性、开始服用多种类抗高血压药物或有90天处方配药的受益人、患有痴呆症、有中风病史以及上一年达到医疗保险D部分覆盖缺口的人群中则较少见。总之,医疗保险受益人中抗高血压药物的低依从性有所下降;然而,停药和低依从性的比例仍然很高。